IRVINE, California, November 17, 2017, CXBS, /PRNewswire/ —
Corix Bioscience Inc. (OTCQB: CXBS) has agreed to co-sponsor Josh Williams’ #90 car in this weekend’s race at Homestead Speedway in Miami, FL. The race, part of the Xfinity series, will be on Saturday, November 18, 2017 at 3:30 EST.
“It is truly an honor to be able to team up with DiMaggio Children’s Hospital to sponsor the #90 Josh Williams car,” commented Michael Ogburn, Corix Bioscience CEO. “It is proof that Josh and Children’s Hospital both see the value our CBD products have in fighting pediatric ailments. I am humbled and thankful that Josh and NASCAR have really looked at the work our company is doing and have taken a further step by allowing us to be a part of this great team. We look forward to a lasting relationship with Josh Williams Racing.”
“It is really special to have Corix Bioscience on board for the championship weekend at Homestead Miami. Not only do we have the opportunity to welcome a new sponsor into the sport but also one whose science can help to improve the lives of so many people who are battling different medical issues. It is a privilege to have the families from Joe DiMaggio Children’s Hospital in attendance; we can’t thank Corix Bioscience and Star Tron enough for making this event possible. I am looking forward to going out there and having a solid run to close out the season as we start preparations and building towards 2018,” said driver, Josh Williams.
Champ RX, a professional boxer-owned company with over 30 title belts between them has partnered with Corix and will have several Boxers and MMA Fighters on hand to tour DiMaggio Children’s Hospital the morning of the race.
About Champ RX LLC.
Champ RX LLC., is a professional boxer-owned company with over 30 title belts between them. They are the first company to offer CBD products that are 100% THC free. They cater to professional athletes as most are tested for THC. Champ RX is working with several professional sports teams and organizations to be able to offer products and conduct research on how CBD products can help with CTE and other brain disease and damage caused by sports. For more information and a list of products, please visit their website.
About Corix Bioscience Inc.
Corix Bioscience Inc. (‘Corix’) is a Wyoming corporation and is fully reporting with the SEC and is listed as OTCQB: CXBS. Corix is the developer of proprietary cannabis and industrial hemp strains using tissue cell cultures to propagate living plants, with plans to patent the strains to be used in the pharmaceutical medical industries.
Our methods allow us to create and breed new and existing plant strains from tissue cells free of any pathogens or disease. We grow these plants to maturity and extract the oils which are the ‘medicine’ part of the plant. Our sales are focused towards the medical industry and we are developing brand named products to be released in early 2018.
Corix’s headquarters is located in Phoenix, Arizona with laboratory and processing facility in Carson City, Nevada and fields for growing the plants in Genoa, Nevada. We are currently looking at expanding our footprint into Washington, Oregon, California and Arizona. The Company’s mission is to create clean and consistent products in medical grade facilities. Consistency being the key which will ultimately yield a safer and superior product, better for people and the environment.
For more information, please visit Corix’s website at http://www.corixbioscience.com.
Forward Looking Statement
This press release, and those statements regarding IXB and the Company, contain forward-looking statements that relate to expectations, beliefs, projections, future plans and strategies, anticipated events and similar expressions. Forward-looking statements may be identified by use of words such as “may,” “will,” “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” or “potential” or similar words or phrases which are predictions of or indicate future events or trends. Statements such as those concerning potential acquisition activity, investment objectives, strategies, opportunities, other plans and objectives for future operations or economic performance are based on the Company’s current expectations, plans, estimates, assumptions and beliefs that involve numerous risks and uncertainties. You are cautioned not to place undue reliance on any forward-looking statements and the Company disclaims any obligation to publicly update or revise any forward-looking statement to reflect changes in underlying assumptions or factors, new information, future events or other changes. Please refer to Company’s filings with the Securities and Exchange Commission for further information.
